Smartlab Europe

Abzena appoints Jim Kennamer as SVP and Site Head of North Carolina

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...
- Advertisement -

Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Jim Kennamer as Senior Vice President and Site Head of North Carolina.

With over 30 years’ experience in the Pharmaceutical industry, Jim has held various positions with increasing levels of responsibilities at Boehringer Mannheim Biochemical, Roche Molecular Biochemicals, Diosynth, Strategene, and Talecris Biotherapeutics/Grifols Therapeutics. For the past six years he has been the Vice President of Global Manufacturing Operations for Immucor in Norcross Georgia.

Jim has deep experience with manufacturing operations and processes, particularly in process improvements. He has driven regulatory compliance and audit readiness for multiple regulatory agencies, established complex supply agreements, and has driven LEAN and right first-time operations throughout his organizations. Jim previously sat on the North Carolina State University Biotechnology Training and Education Center (BTEC) Advisory Board.

Jim has a Bachelor of Science Degree in Biochemistry from Oklahoma State University in Stillwater, Oklahoma and a Doctor of Philosophy, Biochemistry also from Oklahoma State University.

Latest stories

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »